Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06945809 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Guo&'s Distal Entry Tear Repair With WeFlow-EndoPatch System (Gallant Study)

Study acronym: Gallant
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Recruitment opened
    • Start date changed from estimate of Oct 2025 to Jul 13, 2026
    • Enrollment target: 204 to 216
    • Study sites: 0 to 1
    v3
  2. Study title shortened, about 7 wordsv2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
A Multicenter, Randomized Controlled Study About the Safety and Efficacy of WeFlow-EndoPatch Aortic Endovascular Patch System manufactured by EndoNom Medtech (Hangzhou) Co., Ltd. for Chronic Aortic Dissection . (GALLANT Study)
Trial Details
NCT Number NCT06945809
Lead Sponsor Hangzhou Endonom Medtech Co., Ltd.
Conditions
(from sponsor)		 Aortic Dissection, Distal Entry Tear
Related terms Aortic Dissection
Enrollment 216 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov